Literature DB >> 34199556

Thermal Ablation Compared to Partial Hepatectomy for Recurrent Colorectal Liver Metastases: An Amsterdam Colorectal Liver Met Registry (AmCORE) Based Study.

Madelon Dijkstra1, Sanne Nieuwenhuizen1, Robbert S Puijk1, Florentine E F Timmer1, Bart Geboers1, Evelien A C Schouten1, Jip Opperman2, Hester J Scheffer1, Jan J J de Vries1, Rutger-Jan Swijnenburg3, Kathelijn S Versteeg4, Birgit I Lissenberg-Witte5, M Petrousjka van den Tol3, Martijn R Meijerink1.   

Abstract

The aim of this study was to assess safety, efficacy and survival outcomes of repeat thermal ablation as compared to repeat partial hepatectomy in patients with recurrent colorectal liver metastases (CRLM). This Amsterdam Colorectal Liver Met Registry (AmCORE) based study of two cohorts, repeat thermal ablation versus repeat partial hepatectomy, analyzed 136 patients (100 thermal ablation, 36 partial hepatectomy) and 224 tumors (170 thermal ablation, 54 partial hepatectomy) with recurrent CRLM from May 2002 to December 2020. The primary and secondary endpoints were overall survival (OS), distant progression-free survival (DPFS) and local tumor progression-free survival (LTPFS), estimated using the Kaplan-Meier method, and complications, analyzed using the chi-square test. Multivariable analyses based on Cox proportional hazards model were used to account for potential confounders. In addition, subgroup analyses according to patient, initial and repeat local treatment characteristics were performed. In the crude overall comparison, OS of patients treated with repeat partial hepatectomy was not statistically different from repeat thermal ablation (p = 0.927). Further quantification of OS, after accounting for potential confounders, demonstrated concordant results for repeat local treatment (hazard ratio (HR), 0.986; 95% confidence interval (CI), 0.517-1.881; p = 0.966). The 1-, 3- and 5-year OS were 98.9%, 62.6% and 42.3% respectively for the thermal ablation group and 93.8%, 74.5% and 49.3% for the repeat resection group. No differences in DPFS (p = 0.942), LTPFS (p = 0.397) and complication rate (p = 0.063) were found. Mean length of hospital stay was 2.1 days in the repeat thermal ablation group and 4.8 days in the repeat partial hepatectomy group (p = 0.009). Subgroup analyses identified no heterogeneous treatment effects according to patient, initial and repeat local treatment characteristics. Repeat partial hepatectomy was not statistically different from repeat thermal ablation with regard to OS, DPFS, LTPFS and complications, whereas length of hospital stay favored repeat thermal ablation. Thermal ablation should be considered a valid and potentially less invasive alternative for small-size (0-3 cm) CRLM in the treatment of recurrent new CRLM. While, the eagerly awaited results of the phase III prospective randomized controlled COLLISION trial (NCT03088150) should provide definitive answers regarding surgery versus thermal ablation for CRLM.

Entities:  

Keywords:  colorectal liver metastases (CRLM); microwave ablation (MWA); partial hepatectomy (PH); radiofrequency ablation (RFA); recurrence; repeat local treatment; thermal ablation

Year:  2021        PMID: 34199556     DOI: 10.3390/cancers13112769

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  6 in total

1.  Immunofluorescence Assay of Ablated Colorectal Liver Metastases: The Frozen Section of Image-Guided Tumor Ablation?

Authors:  Nikiforos Vasiniotis Kamarinos; Efsevia Vakiani; Sho Fujisawa; Mithat Gonen; Ning Fan; Yevgeniy Romin; Richard K G Do; Etay Ziv; Joseph P Erinjeri; Elena N Petre; Vlasios S Sotirchos; Juan C Camacho; Stephen B Solomon; Katia Manova-Todorova; Constantinos T Sofocleous
Journal:  J Vasc Interv Radiol       Date:  2021-11-17       Impact factor: 3.682

Review 2.  Local Treatments in the Unresectable Patient with Colorectal Cancer Metastasis: A Review from the Point of View of the Medical Oncologist.

Authors:  Javier Torres-Jiménez; Jorge Esteban-Villarrubia; Reyes Ferreiro-Monteagudo; Alfredo Carrato
Journal:  Cancers (Basel)       Date:  2021-11-25       Impact factor: 6.639

3.  An Analysis of Clinicopathological Outcomes and the Utility of Preoperative MRI for Patients Undergoing Resection of Mucinous and Non-Mucinous Colorectal Cancer Liver Metastases.

Authors:  Ian S Reynolds; Paul M Cromwell; Éanna J Ryan; Erinn McGrath; Rory Kennelly; Ronan Ryan; Niall Swan; Kieran Sheahan; Des C Winter; Emir Hoti
Journal:  Front Oncol       Date:  2022-02-21       Impact factor: 6.244

Review 4.  Microwave Ablation, Radiofrequency Ablation, Irreversible Electroporation, and Stereotactic Ablative Body Radiotherapy for Intermediate Size (3-5 cm) Unresectable Colorectal Liver Metastases: a Systematic Review and Meta-analysis.

Authors:  Sanne Nieuwenhuizen; Madelon Dijkstra; Robbert S Puijk; Bart Geboers; Alette H Ruarus; Evelien A Schouten; Karin Nielsen; Jan J J de Vries; Anna M E Bruynzeel; Hester J Scheffer; M Petrousjka van den Tol; Cornelis J A Haasbeek; Martijn R Meijerink
Journal:  Curr Oncol Rep       Date:  2022-03-17       Impact factor: 5.945

5.  Percutaneous cryoablation: a novel treatment option in non-visceral metastases of the abdominal cavity after prior surgery.

Authors:  M Maas; E G Klompenhouwer; D J van der Reijd; T R Baetens; F Gomez Munoz; B M Aarts; M J Lahaye; N M Graafland; C A R Lok; A G J Aalbers; N F M Kok; R G H Beets-Tan
Journal:  Abdom Radiol (NY)       Date:  2022-07-02

6.  Multidisciplinary Tumor Board in the Management of Patients with Colorectal Liver Metastases: A Single-Center Review of 847 Patients.

Authors:  Flavio Milana; Simone Famularo; Antonio Luberto; Lorenza Rimassa; Marta Scorsetti; Tiziana Comito; Tiziana Pressiani; Ciro Franzese; Dario Poretti; Luca Di Tommaso; Nicola Personeni; Marcello Rodari; Vittorio Pedicini; Matteo Donadon; Guido Torzilli
Journal:  Cancers (Basel)       Date:  2022-08-16       Impact factor: 6.575

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.